Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: shakedown who wrote (5918)	11/27/2000 10:09:13 PM
From: Montana Wildhack	Respond to of 14101

Warren, Thank you. I'm pretty sure you're the one who found that previous article as well. Wolf

To: shakedown who wrote (5918)	11/27/2000 10:23:26 PM
From: DaveAu	Read Replies (2) \| Respond to of 14101

Am I the only one disappointed by a March launch? I thought Rebecca previously talked about launching a month after approval or did I dream that ? On another topic, I'm a client of TD. I can assure you they have no shortage of morons there. Dave

To: shakedown who wrote (5918)	11/28/2000 1:14:02 AM
From: Cal Gary	Read Replies (2) \| Respond to of 14101

Hi Warren, I don't mean any disrespect, can you please post your link to the DJ article you posted. I do my DD because this is the "Internet." Unless DJ yanked it, I cannot find it so I cannot confirm it. All I can find is the article below plus the link. NO where does it mention a March date launch date. Also a search on author "Paul Haavardsrud" doesn't yield any such article. Thanks for bringing it to our attention. Index: dowjones.work.com Article: dowjones.work.com Dimethaid Gets Final UK Marketing OK For Pennsaid Monday November 27 8:11am Source: Dow Jones TORONTO -(Dow Jones)- Dimethaid Research Inc. (T.DMX) has received final marketing approval from the U.K. Medicines Control Agency for its PENNSAID Lotion, which is used to treat osteoarthritis. In a news release, Dimethaid said it will immediately seek approvals from other European Union countries. Under the Mutual Recognition procedure prevailing in the EU, the U.K. will act as agent for other EU member states, who can recognize this approval and issue their own authorizations. Member countries include Germany, France and Italy, three of the largest pharmaceutical markets in the world, it noted. The company said this first approval of PENNSAID in an important market "is a significant milestone for Dimethaid," noting there are about 7 million osteoarthritis sufferers in the U.K. Osteoarthritis, or degenerative joint disease, is characterized by the breakdown of cartilage that normally cushions and protects joints from impact. As the cartilage erodes, sufferers experience considerable pain and loss of function. Dimethaid said it expects the commercial launch of PENNSAID "to be an important source of revenue for Dimethaid in 2001 and beyond." It didn't provide a revenue projection. Dimethaid is a pharmaceutical company. Company Web Site: dimethaid.com -Carolyn M. King, Dow Jones Newswires; 416-306-2100 (This story was originally published by Dow Jones Newswires) Copyright (c) 2000 Dow Jones & Company, Inc. All Rights Reserved